CPRX Catalyst Pharmaceuticals Inc.

2.42
-0.01  -0%
Previous Close 2.43
Open 2.43
Price To book 6.05
Market Cap 204623049
Shares 84,554,979
Volume 362,812
Short Ratio 12.37
Av. Daily Volume 831,193

SEC filingsSee all SEC filings

  1. 8-K - Current report 171059280
  2. 8-K - Current report 171018447
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018159
  4. 424B3 - Prospectus [Rule 424(b)(3)] 17990626
  5. EFFECT - Notice of Effectiveness 17984231

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data met endpoints - March 15, 2017. Noted August 30, 2017 that Phase 3 dosing to be initiated early 2018.
Firdapse
MuSK-antibody positive myasthenia gravis (MuSK-MG)
Phase 3 data due 1H 2018.
Firdapse
Congenital Myasthenic Syndromes (CMS)
Refusal to file letter reported on February 17, 2016. Announced that enrollment had commenced in second Phase 3 trial on December 15, 2016. Noted August 30, 2017 that data are due 4Q 2017 with NDA resubmission delayed until early 2018.
Firdapse
Lambert-Easton Myasthenic Syndrome (LEMS)

SEC Filings

  1. 8-K - Current report 171059280
  2. 8-K - Current report 171018447
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018159
  4. 424B3 - Prospectus [Rule 424(b)(3)] 17990626
  5. EFFECT - Notice of Effectiveness 17984231
  6. CORRESP [Cover] - Correspondence
  7. S-3/A [Amend] [Cover] - Registration statement under Securities Act of 1933 17977113
  8. UPLOAD [Cover] - SEC-generated letter
  9. DEL AM - Delaying amendment 17963940
  10. 8-K - Current report 17962113